Roche says it is un­de­terred by up­com­ing biosim­i­lar threat to Vabysmo

Roche’s com­pe­ti­tion in the eye dis­ease space is in­ten­si­fy­ing with Re­gen­eron’s high-dose Eylea and a loom­ing biosim­i­lar chal­lenge, but the Swiss phar­ma said its block­buster …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER